Pro Medicus (PME), a medical imaging software firm, released strong results with revenues up over 30%, underlying NPAT up more than 40%, expanded margins (2-3 times competitors), $180M+ cash balance, no debt, and a record 25-cent fully franked dividend; despite this, shares sold off post-results (down ~60% over six months to ~$280), with analysts like Bell Potter, Citi, and Morgans remaining upbeat on US market share (9%, vast runway) and Europe expansion.[1][7] Gilead Sciences drew positive coverage for base business growth in oncology, HIV (upcoming prevention launch and cell therapy), diversified portfolio, strong cash flow, pipeline, and dividend appeal, prompting investors to double positions.[3][5] Involved parties include PME CEO Dr. Sam Hupert (emphasizing radiologist efficiency amid shortages, AI integration, and fast implementations like 11 months at Baylor Scott & White), analysts (Geoff Meacham/Citi, others), and firms like Citi Research.[1][3][7]
This follows PME's 200% share rise in the prior year and recent US wins, set against 2026 health care pressures like 6-9% premium hikes, rising GLP-1 drug costs, aging demographics, and chronic disease growth; timeline spans PME's February 2025 interview to early 2026 results amid sector shifts to AI, outsourcing, home care (6% EBITDA growth), and HST (8-9% revenue/EBITDA growth to $110B by 2029).[1][2][4][6] Basic context: US dominates global spend (60 cents/dollar), with PME addressing radiologist shortages via efficiency tech.[1]
Newsworthy now due to fresh post-results volatility in high-growth stocks like PME amid 2026 outlooks signaling financial strains (e.g., CMS pressures, high-cost claimants) yet opportunities in AI, post-acute expansion, and innovation—drawing investor focus as health care rebounds in early 2026 after trailing prior years.[2][4][6][10]